


## NSC 140873

Cat. No.:	HY-118365
CAS No.:	106410-13-3
Molecular Formula:	C <sub>13</sub> H <sub>12</sub> ClN <sub>3</sub> O <sub>2</sub>
Molecular Weight:	277.71
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



## BIOLOGICAL ACTIVITY

<b>Description</b>	NSC 140873 is an inhibitor of the RUNX1-CBF $\beta$ interaction. NSC 140873 can be used for research of viral infection and leukemia. NSC 140873 has an unstable structure and can be converted spontaneously in solution to a benzodiazepine (Ro5-3335) <sup>[1][2]</sup> .
<b>In Vitro</b>	NSC 140873 (1 to 100 $\mu$ M, 5-6 days) reduces definitive hematopoiesis in the zebrafish embryos <sup>[2]</sup> . NSC 140873 has antiproliferative activities against cells with high RUNX1 expression <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

[1]. Pu Liu, et al. Methods for treating leukemia and disorders mediated by cbf $\beta$  and runx1 proteins. Patent. WO2012125787A1.

[2]. Cunningham L, et al. Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBF $\beta$  interaction. Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14592-7.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA